SCHEMBL16740747

SCHEMBL16740747

Cc1nc2cc(Cl)ccc2n1-c1nc(N)nc(Nc2ccc(OC(F)F)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 7/20 0.48
AGPAT2 O15120 4/20 0.40
ROCK1 Q13464 1/20 0.39
EGFR P00533 1/20 0.37
IDH1 O75874 1/20 0.37
KCNH2 Q12809 1/20 0.36
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
GALR2 O43603 1/20 0.36
DHFR P00374 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
JAK2 O60674 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748576 0.92 BMI1 (0.53) BMI1AGPAT2ROCK1EGFRKCNH2
SCHEMBL16740812 0.86 BMI1 (0.52) BMI1ROCK1IDH1GALR2DHFR
SCHEMBL16748480 0.86 BMI1 (0.64) BMI1ROCK1
SCHEMBL16748430 0.86 BMI1 (0.45) BMI1AGPAT2ROCK1KCNH2SCN5A
SCHEMBL15741330 0.85 BMI1 (0.47) BMI1ROCK1IDH1GALR2DHFR
SCHEMBL15742534 0.85 BMI1 (0.55) BMI1AGPAT2ROCK1SCN9AGALR2
SCHEMBL16748528 0.83 BMI1 (0.66) BMI1ROCK1GALR2DHFRALDH1A1
SCHEMBL16740804 0.83 AGPAT2 (0.49) BMI1AGPAT2EGFRDHFRKDM4E
SCHEMBL16748578 0.82 BMI1 (0.52) BMI1ROCK1GALR2DHFRNPC1
SCHEMBL16740755 0.80 BMI1 (0.57) BMI1ROCK1IDH1DHFRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885AGPAT2 3973/4885ROCK1 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.